Llwytho...
Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers
Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commonly used subcutaneous injection sites (abdomen, up...
Wedi'i Gadw mewn:
Cyhoeddwyd yn: | Clin Pharmacol Drug Dev |
---|---|
Prif Awduron: | , , , , , |
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
John Wiley and Sons Inc.
2018
|
Pynciau: | |
Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767117/ https://ncbi.nlm.nih.gov/pubmed/30230257 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.617 |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|